Fasoracetam vs Piracetam

Fasoracetam wins for targeted anxiolysis, GABA-B upregulation, and smoothing stimulant edge. It's the community choice for research protocols managing phenibut or stimulant tolerance, and for scenarios where cholinergic racetams exacerbate anxiety or jitter. Ultra-low milligram dosing and rapid sublingual onset are practical advantages, especially when acute relief is the goal.

Piracetam wins for overall safety, stackability, time-tested cognitive support, and minimal metabolic tax. It remains the benchmark racetam for long cycles, stacking protocols, and scenarios where direct cognitive enhancement is prioritized, particularly in fatigued or stressed research models. Its pleiotropic mechanism offers more rounded support, though onset is gradual compared to fasoracetam's fast subjective effects.

Pick Fasoracetam if:

• The research protocol targets anxiety, overstimulation, or phenibut/baclofen tolerance.
• A rapid, sublingual onset of calm is required—within 30–60 minutes.
• Stimulant stacking (caffeine, ADHD meds, clenbuterol) leads to unwanted anxiety or jitter in research settings.
• Need for GABA-B upregulation after chronic GABAergic exposure is documented.
• Cholinergic racetams have proven too stimulating or induce anhedonia in existing research protocols.

Pick Piracetam if:

• The protocol calls for a robust, all-purpose cognitive baseline during mental strain, fatigue, or caloric deficit.
• A foundational racetam is needed to build a stack (with aniracetam, phenylpiracetam, or choline sources).
• Long-term administration and maximum tolerability are primary concerns—no acute CNS overstimulation.
• Onset delay (1–2 weeks) is acceptable for a smoother, less variable benefit curve.
• Cognitive support is sought in research settings involving AAS, dieting, or post-injury models.